{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Antas P"],"funding":["Fundação para a Ciência e a Tecnologia","Institut National Du Cancer","Fondation Aix-Marseille Universite"],"pagination":["24"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12910983"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["31(1)"],"pubmed_abstract":["Inhibition of the phosphatidylinositol kinase vacuolar protein sorting 34 (VPS34) with the pharmacological compound VPS34-IN1 has a range of effects on the dynamics of endosomes. While VPS34 inhibition has been previously suggested as a potential therapeutic approach for treating certain cancers, our findings indicate that it has minimal cytotoxic effects on the leukemic blastic plasmacytoid dendritic cell neoplasm (BPDCN) CAL-1. However, we also found that VPS34-IN1 interferes with the function of this plasmacytoid dendritic cell (pDC) line, by inhibiting Toll-like receptor (TLR)7 signaling. In contrast, VPS34-IN1 triggers activation of the stimulator of interferon genes (STING) and significantly enhances cellular response to the STING agonist 2'3'-cyclic guanosine monophosphate-adenosine"],"journal":["Cellular & molecular biology letters"],"pubmed_title":["VPS34-IN1 potentiates STING-dependent activation in human CAL-1 cells."],"pmcid":["PMC12910983"],"funding_grant_id":["(PLBIO17-187)","CSI","SFRH/BD/138336/2018 , COVID/BD/153248/2023, https://doi.org/10.54499/COVID/BD/153248/2023"],"pubmed_authors":["Ferreira BH","Su B","Nal B","Leite-Pinheiro F","Duarte IF","Mendes A","Reverendo M","Pierre P","Barros D","Gatti E","Carvoeiro D","Arguello RJ","Antas P","Almeida CR","Ramalhinho C","Narita M","Mendes LF","Machado MD"],"additional_accession":[]},"is_claimable":false,"name":"VPS34-IN1 potentiates STING-dependent activation in human CAL-1 cells.","description":"Inhibition of the phosphatidylinositol kinase vacuolar protein sorting 34 (VPS34) with the pharmacological compound VPS34-IN1 has a range of effects on the dynamics of endosomes. While VPS34 inhibition has been previously suggested as a potential therapeutic approach for treating certain cancers, our findings indicate that it has minimal cytotoxic effects on the leukemic blastic plasmacytoid dendritic cell neoplasm (BPDCN) CAL-1. However, we also found that VPS34-IN1 interferes with the function of this plasmacytoid dendritic cell (pDC) line, by inhibiting Toll-like receptor (TLR)7 signaling. In contrast, VPS34-IN1 triggers activation of the stimulator of interferon genes (STING) and significantly enhances cellular response to the STING agonist 2'3'-cyclic guanosine monophosphate-adenosine","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-07-16T00:46:35.037Z","creation":"2026-07-09T10:26:21.074Z"},"accession":"S-EPMC12910983","cross_references":{"pubmed":["41580642"],"doi":["10.1186/s11658-025-00841-4"]}}